Complete remission of CD30-positive diffuse large B-cell lymphoma in a patient with post-transplant lymphoproliferative disorder and end-stage renal disease treated with single-agent brentuximab vedotin

Leuk Lymphoma. 2015 May;56(5):1552-3. doi: 10.3109/10428194.2014.911865.

Authors

Brian T Hill¹, Raymond R Tubbs, Mitchell R Smith

Affiliation

¹ Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic , Cleveland, OH , USA.

PMID: 24717110
DOI: 10.3109/10428194.2014.911865

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Brentuximab Vedotin
Female
Heart Transplantation / adverse effects
Humans
Immunoconjugates / therapeutic use
Ki-1 Antigen / metabolism*
Kidney Failure, Chronic / diagnosis
Kidney Failure, Chronic / etiology*
Lymphoma, Large B-Cell, Diffuse / complications*
Lymphoma, Large B-Cell, Diffuse / metabolism*
Lymphoma, Large B-Cell, Diffuse / therapy
Lymphoproliferative Disorders / diagnosis
Lymphoproliferative Disorders / drug therapy
Lymphoproliferative Disorders / etiology*
Middle Aged
Treatment Outcome

Substances

Immunoconjugates
Ki-1 Antigen
Brentuximab Vedotin